Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Phesgo maintenance after first-line induction in PIK3CA-mutant HER2-positive advanced breast cancer
CTR20232070Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inavolisib in breast cancer, sponsored by Roche. Started Sep 2023; status: active.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232070.